Dr. Krithikaa S

Dr. Krithikaa Sekar is a distinguished radiation oncologist who has graduated from the prestigious Regional Cancer Centre of Tamil Nadu. Driven by a mission to deepen the understanding of cancer beyond routine treatment, Dr. Krithikaa Sekar pursued advanced training in both clinical and basic science research techniques abroad and in Indian Universities. Doctor holds many meritorious presentations and awards at various international forums including ASTRO, ESMO, and IMMUNORAD, and numerous publications in indexed journals.

Dr. Krithikaa is the director of the “Vizhithidu Foundation," which is actively involved in spreading cancer awareness by helping the public understand cancer from a lifestyle perspective. Her notable research contributions include ‘Risk stratifying tongue cancers for personalized treatment’, ‘Understanding the Impact of Glucose on Cancer Cells,’ and ‘Analysing the Role of Pesticides in Breast Cancer Development.’

She is an expert in using new-age radiotherapy technologies, namely the TrueBeam linear accelerator, CyberKnife, and the Ethos adaptive radiotherapy platform.

●       Research:

Dr. Krithikaa has made significant contributions to the field of oncology through her innovative research and leadership roles. As an advocate of precision medicine, she is actively involved in numerous research activities that could potentially improve the quality of cancer care:

⮚     Lead - Mitochondrial Cancer Metabolomics

⮚     Co-Lead - Immuno-Rad in Cancer

⮚     Research Consultant - Artificial Intelligence, Radiomics, and Radio Genomics

⮚     TRAIN Project Co-Investigator-India and Netherlands Collaboration

⮚     Consultant - Siemens AI Project on Auto Contouring

⮚     Co-Investigator - Philips Prostate Habitat Imaging.

⮚     Chief Investigator – LI-RADS Scoring for Liver Using Artificial Intelligence

●       Publications:

Dr. Krithikaa has been involved in numerous research projects and has several publications to her name, including:

⮚     Prognostic Pools in FIGO Stage III-C1 Uterine Cervical Cancer-Implications of Stage Migration –Indian Data. International Journal of Radiation Oncology, Biology, Physics, Volume 108, Issue 3, e492 - e493.

⮚     Next Generation Sequencing-based Genetic Screening in Breast Cancer Risk for Relatives of BRCA Positive Index Cases - A Subcontinent Experience. International Journal of Radiation Oncology, Biology, Physics, Volume 108, Issue 3, e516 - e517.

⮚     Intrastromal Therapy In-sync with Featured Stereotactic Body Radiotherapy (SBRT)- Fixing the Defiant Tumor Microenvironment - a Proof of Concept Study. International Journal of Radiation Oncology, Biology, Physics, Volume 108, Issue 3, S92 - S93.

⮚     A Randomized Control Trial Comparing Time to Healing of Radiation-Induced Acute Skin Reactions Using Biological Membrane Dressing or Topical Methyl Pararosaniline Dye. International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 3, e158.

⮚     FDG-PET Metabolic Vs CT Anatomical Monitoring of Tumor Response to Anterior Chemotherapy in Breast Carcinoma-The Uncertainties. Canc Therapy & Oncol. Int J. 2021; 19(1): 556003.

⮚     Dose Escalation Using Cyberknife Boost in Locally Advanced High Risk Prostatic Carcinoma –A Comparative Study with Historic Cohort Receiving Conventional Fractionated Dose Escalated External Beam Radiotherapy. Open Access J Surg. 2021; 13(2): 5558587.

⮚     FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant, K. Sekar1, R. Lohith2, N. Radheshyam3, K. Kallur1, K. Varun2, S.

⮚     Priya2, S. Siyus2 Annals of Oncology (2020) 31 (suppl_6): S1241-S1254. 10.1016/annonc/ annonc351

⮚     240MO Disparities in the radiotherapy management of cervical carcinoma across the globe: Does the incidence pattern match the infrastructure availability? Annals of Oncology, 31, S1337.